Pulmonx (LUNG) Total Non-Current Liabilities (2019 - 2025)
Pulmonx (LUNG) reported Total Non-Current Liabilities of $75.2 million for Q4 2025, up 94.15% on a QoQ basis from $38.7 million in Q3 2022.
Pulmonx (LUNG) has 5 years of Total Non-Current Liabilities data on file, last reported at $75.2 million in Q4 2025.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $75.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $75.2 million (changed N/A YoY) and the FY2025 annual result came in at $75.2 million, changed N/A from the prior year.
- Total Non-Current Liabilities improved to $75.2 million in Q4 2025 per LUNG's latest filing, from $38.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $75.2 million in Q4 2025 and bottomed at $38.7 million in Q3 2022.
- The 3-year median for Total Non-Current Liabilities is $40.5 million (2022), against an average of $47.3 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 40.52 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 15.78 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 2.44 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 9.85 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 3.53 Bn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 3.47 Bn |
| 10 | Pulmonx | 67.30 Mn | -2.45 Mn | - | 75.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 75.18 Mn |
| Sep 30, 2022 | 38.72 Mn |
| Jun 30, 2022 | 40.37 Mn |
| Mar 31, 2022 | 40.53 Mn |
| Dec 31, 2021 | 41.76 Mn |
| Sep 30, 2020 | 68.63 Mn |
| Dec 31, 2019 | 34.41 Mn |